Summit Therapeutics reports Phase III biliary‑cancer trial shows overall‑survival superiority
Summit Therapeutics announced that its antibody ivonescimab combined with chemotherapy improved overall survival versus durvalumab plus chemotherapy in a Chinese Phase III study of advanced biliary tract cancer. The trial enrolled 682 patients and yielded a hazard ratio of 0.75 (95 % CI 0.61‑0.92) with a one‑sided p‑value of 0.0031. Median overall survival was 14.9 months for ivonescimab versus 12.1 months for the comparator, a 25 % reduction in risk of death. The company also disclosed a separate U.S. Phase 2/3 trial to start in Q4 2026 and reported $690.7 million in cash as of June 30.
Why it matters
The survival win could enhance Summit’s valuation by supporting future regulatory filings and expanding its pipeline, while the strong cash balance provides runway for the upcoming U.S. trial.
Key facts
- 1The randomized, double‑blind HARMONi‑GI1 study enrolled 682 patients, with 340 assigned to ivonescimab plus chemotherapy and 342 to durvalumab plus chemotherapy. mugglehead.com
- 2Median overall survival was 14.9 months with ivonescimab versus 12.1 months with durvalumab, a 25 % reduction in death risk. mugglehead.com
- 3The overall‑survival hazard ratio was 0.75 (95 % CI 0.61‑0.92) with a one‑sided p‑value of 0.0031 at interim analysis. mugglehead.com
- 4Median progression‑free survival was 8.4 months for ivonescimab and 5.8 months for durvalumab. mugglehead.com
- 5Objective response rates were 53.8 % for ivonescimab and 32.5 % for durvalumab. mugglehead.com
- 6Summit reported cash and investments of US$690.7 million as of June 30. mugglehead.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.